Fenofibrate Dosing Recommendations
For adults with normal renal function, start fenofibrate at 160 mg once daily with meals for primary hypercholesterolemia or mixed dyslipidemia, or 54-160 mg daily for severe hypertriglyceridemia, with mandatory renal function assessment before initiation and every 3-6 months thereafter. 1
Standard Dosing by Indication
Primary Hypercholesterolemia or Mixed Dyslipidemia
- Initial dose: 160 mg once daily with meals 1
- This represents the standard starting dose for lipid management in patients with normal renal function
Severe Hypertriglyceridemia
- Dose range: 54 mg to 160 mg once daily 1
- Maximum dose: 160 mg once daily 1
- Individualize dosing based on lipid response at 4-8 week intervals
- If no adequate response after 2 months at maximum dose, discontinue therapy 1
Critical Renal Dosing Adjustments
Renal function assessment is mandatory before starting fenofibrate and must be monitored closely, as this is where most prescribing errors occur. 2
Mild to Moderate Renal Impairment (eGFR 30-59 mL/min/1.73 m²)
- Start at 54 mg once daily 1
- Do not exceed 54 mg/day 2
- Increase dose only after evaluating renal function and lipid response at this initial dose 1
- Monitor renal function within 3 months of initiation, then every 6 months 2
Severe Renal Impairment (eGFR <30 mL/min/1.73 m²)
- Contraindicated - do not use 2, 1
- This includes patients on dialysis 1
- If eGFR drops persistently to <30 mL/min/1.73 m² during treatment, discontinue fenofibrate immediately 2
Monitoring Requirements
The ACC/AHA guidelines provide Class I (strong) recommendations for monitoring 2:
- Before initiation: Assess serum creatinine and calculate eGFR
- Within 3 months: Repeat renal function tests
- Every 6 months thereafter: Continue monitoring renal status
- Lipid panel: Check at 4-8 weeks after initiation or dose adjustment
Common Pitfall to Avoid
Fenofibrate causes a reversible increase in serum creatinine (typically 9-10% increase) that occurs within weeks of starting therapy 3, 4. This does not necessarily indicate true nephrotoxicity but requires close monitoring. However, increases ≥30% warrant consideration of discontinuation 3. The creatinine elevation is often reversible even without stopping the drug, but vigilance is essential, particularly in elderly patients or those on ACE inhibitors/ARBs 3.
Geriatric Patients
- Dose selection based entirely on renal function 1
- Elderly patients are at higher risk for fenofibrate-associated creatinine increases 3, 4
- Calculate eGFR and follow renal dosing guidelines above
- More frequent monitoring may be warranted
Administration
- Always give with meals to optimize bioavailability 1
- Multiple fenofibrate formulations exist with different dosing; consult specific product labeling 2
Important Safety Considerations
Do not combine fenofibrate with gemfibrozil and statins - gemfibrozil significantly increases rhabdomyolysis risk 2. Fenofibrate may be considered with low- or moderate-intensity statins only when benefits outweigh risks, particularly for triglycerides ≥500 mg/dL 2.
The 2021 Canadian guidelines note that when icosapent ethyl is not indicated but triglycerides require management (very high TG ≥10 mmol/L or concern for pancreatitis), micronized fenofibrate is the preferred fibrate 5.